This summer, we have been fortunate enough to have been asked to speak at the 2017 Association of Healthcare Resource and Materials Management conference (AHRMM17). The organization is the premier membership group for healthcare supply chain professionals and we’re honored to have been invited back to speak. This year, we will present “Value Analysis and Evidence: The Keys to Bundled Payment Success."Read More
Despite the instability facing the American healthcare landscape at present, there continues to be growing focus on value. The Patient Protection and Affordable Care Act (ACA) has placed an increased emphasis on healthcare quality and patient satisfaction, especially with regard to Medicare reimbursement. Private payers are also seeking payment structures based on patient outcomes. In the face of such economic pressures, deciding which technologies to incorporate into patient care is a challenge, and will continue to be so in the future as new health technologies and brands enter the market. To meet clinical as well as financial goals, providers need to make sure that the health technologies they adopt are safe and have proven benefit, and are cost-effective.Read More
You might notice a preponderance of people wearing purple this month. That’s because it’s the signature color of the Alzheimer’s Association’s “Go Purple” initiative to raise awareness about the devastating effects of the disease. Discovered by Dr. Alois Alzheimer in 1906, the disease is defined by the National Institute on Aging (NIA) as “an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks.” It is estimated that more than 5 million Americans may have Alzheimer’s, and that it may rank as the third most common cause of death for older people, superseded only by cancer and heart disease.Read More
We have reached the end of our 4-part series! We hope you and your fellow supply chain and value analysis professionals found the information useful and have shared it with your peers. Don’t forget, you can also download our free eBook, Evidence: The 5th Domain of Value-Based Purchasing to read the content of this series in one complete package.
Didn’t read part 3? Here’s part 3.
Without further ado, we will review our fourth and final VBP domain as well as talk about the link between evidence and executive compensation.Read More
Welcome back for part 3 of our 4-part series! We’re just past the halfway mark in our effort to tell you about the impact of evidence on value-based purchasing (VBP). If you found the previous installments informative, please share these blogs with your fellow supply chain and value analysis professionals. Don’t forget, you can also download our free eBook, Evidence: The 5th Domain of Value-Based Purchasing to read the content of this series in one complete package.
Need to catch up? Here’s part 2.
Let’s review our third VBP domain: Clinical Care (Outcomes and Process).Read More
Last week, as part of their “Your Health” segment, NPR aired a piece about the effectiveness of various treatments for low back pain, with a focus on spinal manipulation. Lower back pain is a common complaint to physicians, and, as the article states, a common reason for the prescription of addictive narcotic painkillers. Other interventions can include:
- Physical therapy
- Massage therapy
- Nonsteroidal anti-inflammatory drugs (NSAIDS)
- Chiropractic treatment
Who doesn’t love lists? Especially lists detailing the best of the best, the most popular, the most in-demand. To that end, we’ve compiled a list of our top three Directory reports for the first three months of the year, in order of retrievals from our Knowledge Center. These three represent a mix of information important to both payers and providers.
If you’re already a subscriber, you can check out these reports at any time. If you’re not a Hayes member…what are you waiting for? Don’t forget, you can also purchase an individual report. Contact us to find out how.
Let’s get to the top three!Read More
Last week, I had the distinct privilege of presenting the keynote at the first annual Northeast Regional Conference of the Association of Healthcare Value Analysis Professionals (AHVAP). With the ever-increasing push away from fee-for-service and toward value-based healthcare, I thought it pertinent to discuss the role of value analysis in the success of a health system’s bundled payment initiatives. Specifically, I wanted to highlight the role evidence can play in assisting value analysis professionals in their evidence-based decision making, as well as how it can help them define the part they play in the value-based purchasing environment.Read More
In early March, Becker’s Hospital Review reported that MD Anderson Cancer Center placed their Oncology Expert Advisor project on hold. Announced in 2013, the joint effort between the hospital and the software giant was to be a revolutionary step forward in the use of “big data” to significantly improve clinical decision making and healthcare delivery. The article cites a number of reasons as to why the initiative was sidelined, not the least of which was cost. However, according to the article, a far more interesting complication arose involving MD Anderson’s electronic health record (EHR) system, which was changed after the program had begun. IBM Watson’s technology no longer communicated with the new EHR system and therefore had outdated information.Read More
Traditional cancer treatments include procedures with which we’re all familiar: chemotherapy, surgery, and radiation therapy. But clinicians and scientists continue to work tirelessly to find a cure for the devastating disease. While immunotherapy has been in the news as of late as relates to the treatment of peanut allergies (see our blog, Peanut Allergy Drug Therapies Make National Headlines), there have been advances in its use for the treatment of cancer over the past few years. There are several biologic agents that are FDA approved for different cancers; these targeted therapies are aimed at destroying cancer cells without the troublesome side effects that accompany traditional cancer treatments.
But there’s something new on the horizon from the world of immunotherapy.Read More